JP2022509206A - Magl阻害剤による疾病の治療方法 - Google Patents

Magl阻害剤による疾病の治療方法 Download PDF

Info

Publication number
JP2022509206A
JP2022509206A JP2021529827A JP2021529827A JP2022509206A JP 2022509206 A JP2022509206 A JP 2022509206A JP 2021529827 A JP2021529827 A JP 2021529827A JP 2021529827 A JP2021529827 A JP 2021529827A JP 2022509206 A JP2022509206 A JP 2022509206A
Authority
JP
Japan
Prior art keywords
disease
condition
compound
formula
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509206A5 (cg-RX-API-DMAC7.html
Inventor
ロドニー ビールス,チャニング
ジョーンズ,ダラス
ロバート クラッパー,ジェーソン
ポール オニール,ゲーリー
ピーター フレーザー,イアン
ロレイン ブランクマン,ジャクリーン
ジェィ.エム. ウィーナー,ジョン
エー. グライス,シェリル
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2022509206A publication Critical patent/JP2022509206A/ja
Publication of JP2022509206A5 publication Critical patent/JP2022509206A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021529827A 2018-11-28 2019-11-26 Magl阻害剤による疾病の治療方法 Pending JP2022509206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772554P 2018-11-28 2018-11-28
US62/772,554 2018-11-28
PCT/US2019/063451 WO2020112905A1 (en) 2018-11-28 2019-11-26 Methods of treating disease with magl inhibitors

Publications (2)

Publication Number Publication Date
JP2022509206A true JP2022509206A (ja) 2022-01-20
JP2022509206A5 JP2022509206A5 (cg-RX-API-DMAC7.html) 2022-11-28

Family

ID=70851863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529827A Pending JP2022509206A (ja) 2018-11-28 2019-11-26 Magl阻害剤による疾病の治療方法

Country Status (15)

Country Link
US (1) US20220031676A1 (cg-RX-API-DMAC7.html)
EP (1) EP3886844A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022509206A (cg-RX-API-DMAC7.html)
KR (1) KR20210097734A (cg-RX-API-DMAC7.html)
CN (1) CN113347971A (cg-RX-API-DMAC7.html)
AU (1) AU2019389017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015043A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120577A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001363A1 (cg-RX-API-DMAC7.html)
IL (1) IL283508A (cg-RX-API-DMAC7.html)
MA (1) MA54313A (cg-RX-API-DMAC7.html)
MX (1) MX2021006312A (cg-RX-API-DMAC7.html)
SG (1) SG11202105320YA (cg-RX-API-DMAC7.html)
WO (1) WO2020112905A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103975B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200738A (en) 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Cdk2抑制劑及其使用方法
AU2022318349B2 (en) 2021-07-30 2025-12-18 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
CA3234430A1 (en) * 2021-11-02 2023-05-11 Samuel George ANDREW Crystalline forms of a monoacylglycerol lipase inhibitor
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087854A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US20170247387A1 (en) * 2014-07-25 2017-08-31 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
WO2018134698A1 (en) * 2017-01-23 2018-07-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010239188B2 (en) * 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2017087858A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
KR20170128029A (ko) * 2016-05-13 2017-11-22 삼성에스디아이 주식회사 태양전지 전극 형성용 조성물 및 이로부터 제조된 전극
MY200738A (en) * 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
US10927105B1 (en) * 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170247387A1 (en) * 2014-07-25 2017-08-31 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
WO2017087854A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2018134698A1 (en) * 2017-01-23 2018-07-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors

Also Published As

Publication number Publication date
BR112020015043A2 (pt) 2021-08-31
EP3886844A4 (en) 2022-08-24
IL283508A (en) 2021-07-29
AU2019389017A1 (en) 2021-06-10
SG11202105320YA (en) 2021-06-29
EP3886844A1 (en) 2021-10-06
KR20210097734A (ko) 2021-08-09
WO2020112905A1 (en) 2020-06-04
ZA202103975B (en) 2023-11-29
MX2021006312A (es) 2021-08-11
CL2021001363A1 (es) 2021-11-12
US20220031676A1 (en) 2022-02-03
MA54313A (fr) 2022-03-09
AU2019389017B2 (en) 2025-01-09
CN113347971A (zh) 2021-09-03
CA3120577A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
KR20210097734A (ko) Magl 저해제에 의해 질병을 치료하는 방법
US11634418B2 (en) Amino acid compounds and methods of use
JP7042468B2 (ja) Magl阻害剤
JP6987859B2 (ja) Magl阻害剤
WO2017087858A1 (en) Pyrazole compounds and methods of making and using same
WO2019226991A1 (en) Androgen receptor modulators and methods for their use
TW201125585A (en) Quaternary ammonium salt prodrugs
JP2020504707A (ja) Magl阻害剤
TW201011022A (en) Quinuclidine carbonate derivatives and medicinal composition thereof
JP7578602B2 (ja) P2x3修飾薬での治療
WO2016105448A1 (en) Imidazoline receptor type 1 ligands for use as therapeutics
CA3213289A1 (en) Phenalkylamines and methods of making and using the same
JP6929857B2 (ja) 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド
JP2022523668A (ja) Magl阻害剤による疾病の治療方法
TWI784199B (zh) Dp拮抗劑
US8076485B2 (en) Methylphenidate derivatives and uses of them
PT95735B (pt) Processo para a preparacao de morfolinois e de composicoes farmaceuticas que os contem
MX2007016217A (es) Compuestos de alfa-(aril- o heteroaril-metil)-beta-piperidinopropa namida como antagonista del receptor orl1.
JP3112356B2 (ja) シクロペンテノン化合物及び該化合物を有効成分とする脳機能改善薬
WO2025155874A1 (en) Methods and compounds for modulating immune response
JPS6233237B2 (cg-RX-API-DMAC7.html)
JP2013112657A (ja) フェノキシメチルベンズアミド誘導体、その薬学的に許容される酸付加塩及びその医薬用途
BR122023003660B1 (pt) Compostos inibidores duplos de magl e faah, composição farmacêutica e usos
BR122022025791B1 (pt) Compostos inibidores duplos de magl e faah, composição farmacêutica e usos
BR122022025803B1 (pt) Compostos inibidores duplos de magl e faah, composição farmacêutica e usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240312